



ASX Announcement

16 October 2025

2025 AGM CEO Presentation

In accordance with ASX Listing Rule 3.13.3, Cambium Bio Limited (ASX:CMB) (**Cambium Bio, Cambium or Company**), attaches the CEO's presentation to be delivered at the Annual General Meeting (**AGM**) today in Sydney.

This announcement was authorised by the Board of Directors of Cambium Bio Limited.

- END -

For further information, please contact:

Cambium Bio Limited
Unit 2.06/31 Lexington Dr, Bella Vista, NSW 2153, Australia
ABN 13 127 035 358
Phone: 1300 995 098
www.cambium.bio

About Cambium Bio Limited

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit www.cambium.bio



A pioneering regenerative medicine
platform in ophthalmology and
tissue repair

CEO Address
Annual General Meeting
FY2025

Cambium Bio Limited
ASX:CMB

16 October 2025



Cambium Bio Overview

Overview

- Cambium Bio Limited (CBL) is a clinical-stage regenerative medicine company
- Focused on developing innovative biologics for ophthalmology and tissue repair
- Lead product candidate: Elate Ocular® for dry eye disease, multibillion-dollar indication with significant unmet need
- Advancing Elate Ocular® towards pivotal Phase 3 clinical trials in Q4 CY 2025
- Proprietary technology platform based on fibrinogen-depleted human platelet lysate
- A\$ 25M of successfully invested capital in the development of Elate Ocular®
- Manufacturing process established with Zheng Yang Biomedical Technology
- Pipeline includes Progenza™ for knee osteoarthritis and Sygenus for wound healing
- Company sale or out-licensing options to be explored after launching Phase 3 trials

Clinical pipeline

Drug	Technology	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Reg.
Elate Ocular®	FD-HPL	Dry eye disease					
Progenza™	MSC & Secretome	Knee osteoarthritis					
Sygenus	Secretome	Wound healing					

Financial information

Share price (14 Oct 2025) A\$ 0.475

Shares issued (pro-forma*) 22.97 M


Market capitalisation (pro-forma) A\$ 10.91M

Cash (as of 28 Aug 2025 – pro-forma) A\$ 2.34M

Debt (as of 30 Jun 2025) A\$ 0.48M

Enterprise value (pro-forma) A\$ 9.05M

Shareholders



Pro-forma
as of 14 Oct 2025

Note: * pro-forma adjustment for additional shares to be issued in October 2025 following the A\$2.17M capital raise announced on 30 July 2025

Board and Executive Team



Dr Edmund Waller, MD, PhD
Chief Scientific Officer
Board Chair

- Co-founder of Cambium Medical Technologies in 2013
- Professor of Medicine, Pathology & Hematology at Emory University, Atlanta, GA
- Multiple other roles at Emory University, Atlanta, GA
- PhD at The Rockefeller University, New York City, NY
- MD at Cornell University Medical College, Ithaca, NY
- BA at Harvard University, Cambridge, MA



Karolis Rosickas, MS, MBA
Chief Executive Officer

- Co-founder of cell therapy CDMO SingCell, Singapore
- Co-founder of digital therapeutics company OME Health, London, UK
- Vice President, Healthcare Investment Banking, HSBC, London, UK
- Finance Director, Danone Early Life & Clinical Nutrition
- MS Biotechnology at Northeastern University, Boston
- MBA at IESE Business School, Barcelona, Spain
- Joined Cambium Bio in 2020



Dr Neera Jagirdar, MD, MPH
VP, Clinical Development

- Over 15 years of experience in the design and conduct of experimental research studies and clinical trials in support of new product development and quality assurance
- MD at American University of Antigua, Osbourn, Antigua and Barbuda
- MPH at American Public University, Charles Town, WV
- BA at Boston University, Boston, MA
- Joined Cambium Bio in 2017



Dennis Hannigan, MS
VP, CMC and Quality

- 30+ years of international experience in biologics, medical devices, and pharmaceuticals
- Expertise in quality management systems, regulatory affairs, and clinical strategies
- Extensive experience with FDA regulations, ISO standards, and global regulatory agencies
- Multiple industry certifications including RAC, ASQ CQA, and Lean Six Sigma Green Belt
- Joined Cambium Bio in 2016



Terence Walts, MBA
Non-Executive Director

- Co-founder of Cambium Medical Technologies in 2013
- CEO of 3Ti (automated blood analyzer start-up)
- CEO of Refocus Group (ophthalmic device start-up)
- CMO of Autonomous Technologies (refractive surgery start-up)
- VP WW Sales, Marketing and BD at Novartis/CIBA
- MBA at The University of Notre Dame, Indiana
- BS in Marketing at Indiana University, Indiana



Dr Sebastian Tseng, DDS, MBA
Non-Executive Director

- Chairman of Zheng Yang Biomedical Technology Co., Ltd. (ZYBT), a holding company for AventaCell, Dr. Wells, and other biomedical and healthcare businesses
- Assistant Professor at Taipei Medical University
- Chairman of Asia Pacific Academy of Implant Surgery
- Doctor of Dental Surgery at the College of Dentistry of New York University
- Bachelor of Dental Surgery at College of Chung Shan Medical University



A/Prof Denese C Marks, PhD
Non-Executive Director

- Expert in blood and platelet-derived biologics with 20+ years in transfusion science
- Led development of clinical-grade autologous serum eye drops at the Australian Red Cross
- Former National R&D Director, Australian Red Cross Lifeblood
- PhD in Medical Science, University of Sydney; Postdoc at Harvard Medical School



A/Prof Chandra Bala, MD, PhD
Non-Executive Director

- Clinical A/Prof and Senior Partner at PersonalEyes, operating 12 ophthalmology clinics across Australia
- Practicing corneal surgeon at Macquarie University Hospital, specialising in cornea and refractive surgery
- Extensive experience in Phase 2-4 ophthalmic clinical trials with numerous publications
- MBBS and PhD qualifications with expertise in treating ocular surface diseases

Note: other Non-Executive Directors include Dr Chi-Tai Chang, Chief Strategy Officer at Orient EuroPharma (4120.TWO), and Li-Chien Chiu, Chairman of Hocheng Corporation (1810.TW)

FY2025 Transformative Year for Cambium Bio



Successfully integrated
Cambium Medical
Technologies team and the
clinical asset post-merger



Strengthened balance
sheet with A\$5.1M strategic
placements from strategic
investors



Completed required CMC
activities to initiate
registration-enabling
Phase 3 trials in dry eye



Enhanced corporate
governance and
operational capabilities

Advancing Elate Ocular® Towards Phase 3

Key development milestones

- ✓ FDA Fast Track designation granted (Dec-2024), enabling closer FDA interaction and eligibility for accelerated approval
- ✓ Phase 3 protocol approved by FDA (Feb-2025); two identical MRCT trials (CAMOMILE-2/-3) with signs (tCFS) and symptoms (Eye Discomfort VAS) co-primary endpoints
- ✓ Potency assay strategy accepted (Mar-2025) for lot release and comparability through to BLA
- ✓ Ethics approvals secured in the US (Advarra IRB, 9 May) and Australia (Bellberry HREC, 26 Jun)
- ✓ FDA confirms clearance to commence Phase 3 dosing (Jul-2025)
- ✓ Operational readiness: cGMP drug product manufacturing; CRO award and site activations underway



Proteins
Growth factors
Vitamins
Antioxidants
Electrolytes

Elate Ocular Licensing Deal in Europe and Saudi Arabia


Benta Group



Commercial Manufacturing of Elate Ocular in Taiwan



Licensing of Fibrin Biologic



Strategic Outlook

Key activities and near-term catalysts

- Phase 3 trial First-Patient-In (FPI) planned for Q4 CY2025, subject to additional financing
- Multi-centre studies (n=800) across the US and Australia
- Licensing and M&A discussions with Big and Specialty Pharma to commence after FPI
- Phase 3 topline data expected in Q4 CY2026
- Capital raising activities underway



Contact details

Karolis Rosickas
Chief Executive Officer
kr@cambium.bio
+65-98112075
+61-404626029

Cambium Bio Limited

www.cambium.bio
1 300 995 098
ABN 13 127 035 358
Unit 2.06/31 Lexington Drive, Bella Vista
NSW 2153, Australia